-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Part A of the Phase 2/3 study for patients with new coronary pneumonia who have developed symptoms but do not require hospitalization by oral administration of RHB-107 (upamostat) once a day has completed patient recruitment
-Part A of this study, which aims to evaluate the safety and tolerability of RHB-107 and dose selection, is expected to release top-line results in the first quarter of 2022
RHB-107 is a new experimental antiviral serum protease inhibitor targeting human cytokines, which is expected to be effective against emerging virus variants
-At the same time, RedHill's data package of opaganib[2], another advanced new oral new coronary pneumonia drug candidate, has been submitted to regulatory agencies in the United States, the European Union, and the United Kingdom in advance of the planned regulatory proposal
Tel Aviv, Israel and Raleigh, North Carolina, November 17, 2021/PRNewswire/ - Specialty biopharmaceutical company RedHill Biopharma Ltd.
This phase 2/3 study (NCT04723527) for RHB-107 aims to evaluate its use in the treatment of patients with early-stage symptomatic new coronary pneumonia.
RedHill Medical Director Terry F.
RHB-107 is a new anti-viral drug candidate that can target human serine proteases, which are involved in the synthesis of spike proteins, allowing the virus to enter target cells
At the same time, RedHill's other advanced new oral new coronary pneumonia drug candidate opaganib[2] data package has been submitted to regulatory agencies in the United States, the European Union, and the United Kingdom in advance of the planned regulatory recommendations
About RHB-107 (upamostat)
RHB-107 is a proprietary technology, the first of its kind, an oral antiviral agent, which can target human serine protease, which is involved in the synthesis of spike protein to enable the virus to enter the target cell
About RedHill Biopharma
RedHill Biopharma Ltd.
Note: This press release is a translation of the company's official press release issued in English, and is provided for your convenience
Category: R&D
1.
2.
3.
4.
5.
